evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

283 questions · 285 findings · 33 reviews · Epilepsy

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 31 · 10.9%GRADE not reported 13 · 4.6%Very low 33 · 11.6%Low 80 · 28.1%Moderate 96 · 33.7%High 32 · 11.2%

Zonisamide vs placebo

Frequency of adverse effects ‐ dizziness ( · people with focal epilepsy

Zonisamide probably leads to higher adverse effects: dizziness (whole treatment period; any dose) compared with placebo (moderate certainty).

1 finding from 1 review

Zonisamide vs placebo

Adverse effect: fatigue · people with focal epilepsy

Zonisamide probably leads to higher adverse effects: fatigue (whole treatment period; any dose) compared with placebo (moderate certainty).

1 finding from 1 review

Zonisamide vs placebo

Nausea · people with focal epilepsy

Zonisamide probably leads to higher adverse effects: nausea (whole treatment period; any dose) compared with placebo (moderate certainty).

1 finding from 1 review

Zonisamide vs placebo

Somnolence · people with focal epilepsy

Zonisamide probably leads to higher adverse effects: somnolence (whole treatment period; any dose) compared with placebo (moderate certainty).

1 finding from 1 review

Vigabatrin vs placebo

50% or greater reduction in seizure frequency · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin may leads to higher ≥ 50% reduction in seizure frequency (ITT analysis) Duration of… compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Treatment withdrawal for any reason Duration of treatment (range): 12 (3 months) to 36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy

It is very uncertain whether vigabatrin changes treatment withdrawal for any reason Duration of treatment (range):… compared with placebo (very low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Ataxia · people (aged 10–64 years) with drug‐resistant focal epilepsy

It is very uncertain whether vigabatrin changes adverse effects: ataxia Duration of treatment (range): 7–36 weeks compared with placebo (very low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effects: dizziness, lightheadedness · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin may leads to higher adverse effects: dizziness/light‐headedness Duration of treatment… compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effect: fatigue · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin may leads to higher adverse effects: fatigue Duration of treatment (range): 8–36 weeks compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effects: nystagmus Duration of treatment (range): 16–18 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin showed no clear difference in adverse effects: nystagmus Duration of treatment (range): 16–18 weeks compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effects: abnormal vision Duration of treatment (range): 8–36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy

It is very uncertain whether vigabatrin changes adverse effects: abnormal vision Duration of treatment (range): 8–36… compared with placebo (very low certainty).

1 finding from 1 review

Rufinamide vs placebo

50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy

Rufinamide probably leads to higher 50% or greater reduction in seizure frequency ‐ ITT analysis compared with placebo (moderate certainty).

1 finding from 1 review

Rufinamide vs placebo

Frequency of adverse effects ‐ dizziness ( · people with drug‐resistant focal epilepsy

Rufinamide probably leads to higher adverse effects: dizziness compared with placebo (moderate certainty).

1 finding from 1 review